Singapore vs Switzerland: Previously treated cases tested for RR-/MDR-TB
Singapore
49.0%
in 2024
Switzerland
48.0%
in 2024
Singapore rank
151st
Switzerland rank
153rd
Previously treated cases tested for RR-/MDR-TB over time
- Singapore
- Switzerland
How they compare
Singapore currently reports 49.0% against 48.0% in Switzerland, a difference of 1.0%.
The two have swapped places 4 times across 20 shared years of data; in 2005 it was Singapore ahead.
Singapore ranks 151st and Switzerland ranks 153rd of 180 countries.
Across the 3 decades both report, Singapore averaged higher in 2 and Switzerland in 1.
Head to head by decade
| Decade | Singapore | Switzerland | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 66.6% | 73.0% | 6.4% | Switzerland |
| 2010s | 68.5% | 64.4% | 4.1% | Singapore |
| 2020s | 72.2% | 36.6% | 35.6% | Singapore |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher previously treated cases tested for rr-/mdr-tb, Singapore or Switzerland?
- Singapore, at 49.0% against 48.0% in Switzerland as of 2024.
- What is the difference in previously treated cases tested for rr-/mdr-tb between Singapore and Switzerland?
- 1.0%, with Singapore ahead.
- How many years of comparable data are there for Singapore and Switzerland?
- 20 years are reported by both, from 2005 to 2024.
- How do Singapore and Switzerland rank globally for previously treated cases tested for rr-/mdr-tb?
- Singapore ranks 151st and Switzerland ranks 153rd of 180 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Previously treated cases tested for RR-/MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.